Oral sessions summaries


Acute and Chronic Complications

Results of the eValuation of ERTugliflozinEffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)

Richard E. Pratley, MD; Samuel Dagogo-Jack, MD, DSc; Christopher P. Cannon, MD; Darren K. McGuire, MD, MHSc; David Z. Cherney, MD, PhD; Mark E. Cooper, MBBS, PhD

Expert Commentary by Mark Cooper, MB, BS, PhD

ADA 2020 - Oral session

View
Acute and Chronic Complications

DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!

John J.V. McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, FRCP, FESC; Mikhail N. Kosiborod, MD; Silvio E. Inzucchi, MD; Jeffrey M. Testani, MD, MTR

Expert Commentary by Prof. Francesco Giorgino, MD

ADA 2020 - Oral session

View
Acute and Chronic Complications

Analyses of First Plus Recurrent Cardiovascular and Hospitalization Events in the CAROLINA Trial

Nikolaus Marx, MD

Expert Commentary by Luca Monge, MD

ADA 2020 - Oral session

View
Acute and Chronic Complications

Association of Frequency of Hypoglycemic Episodes with Incident Cardiovascular Events in Adults with Type 2 Diabetes Mellitus: A National Database Study

Aman Rajpal, MD

Expert commentary by Luca Monge, MD

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

Efficacy and Safety of Dulaglutide 3 mg and 4.5 mg vs. Dulaglutide 1.5 mg: 52-Week Results from AWARD-11

Juan P. Frias, MD

Expert Commentary by Paolo Fiorina, MD, PhD and Ida Pastore, MD

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

Acute Declines in eGFR During Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

Megumi Oshima, MD

Expert Commentary by Luca Monge, MD

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Jing Wei Li, MD

Expert Commentary by Martin Haluzík, MD

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER

Suzanne V. Arnold, MD, MHA

Expert commentary by Vivian A. Fonseca, MD, FRCP

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

Advanced Hybrid Closed-Loop Pivotal Safety Study

Bruce Bode, MD

Expert commentary by Amy Sanghavi Shah, MD, MS

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

FLAIR—An NIDDK-Sponsored International, Multisite Randomized Crossover Trial of AHCL vs. 670G

Richard M. Bergenstal, MD

Expert commentary by Amy Sanghavi Shah, MD, MS

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

New Zealand AHCL Randomized Crossover Trial

Martin de Bock, FRACP, PhD

Expert commentary by David Maahs, MD, PhD

ADA 2020 - Oral session

View
Clinical Diabetes/Therapeutics

Horizon Automated Glucose Control System Pre-pivotal Trial Data

Bruce A. Buckingham, MD

Expert commentary by Amy Sanghavi Shah, MD, MS

ADA 2020 - Oral session

View
Epidemiology/Genetics

New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)

David M. Nathan, MD; Mark Molitch, MD; Ronald B. Goldberg, MD; Brandy M. Heckman-Stoddard, PhD, MPH;Jose A. Luchsinger-Stuart, MD, MPH

Expert commentary by Dana M. Dabelea, MD, PhD

ADA 2020 - Oral session

View
Epidemiology/Genetics

Update from the TEDDY Study

Marian Rewers, MD, PhD; Qian Li, PhD; Kendra Vehik, PhD, MPH; William Hagopian, MD, PhD

Expert Commentary by Prof. Tatjana Milenkovic, MD

ADA 2020 - Oral session

View
Epidemiology/Genetics

Twenty Years of Pediatric Diabetes Surveillance- What Do We Know and Why It Matters - The SEARCH for Diabetes in Youth Study

Jean M. Lawrence, ScD, MPH, MSSA; Amy K. Mottl, MD, MPH, FASN; Katherine A. Sauder, PhD; Catherine Pihoker, MD

Expert commentary by Dana M. Dabelea, MD, PhD

ADA 2020 - Oral session

View
Epidemiology/Genetics

Population Health Efforts in the Prevention and Treatment of Diabetes

Natalie D. Ritchie, PhD; Matthew J. O’Brien, MD, MS; Brian J. Wells, MD, PhD; Simon Griffin, FRCGP, FMedSci

Expert Commentary by Prof. Florian Toti, MD

ADA 2020 - Oral session

View
Immunology/Transplantation

All-Cause Mortality over 16 Years in Look AHEAD

Rena R. Wing, PhD

Expert Commentary by Martin Haluzík, MD

ADA 2020 - Oral session

View
Immunology/Transplantation

Comparison of Pancreas vs. Islet Transplantation Outcomes from a Large Single Center

Braulio A. Marfil-Garza, MD

ADA 2020 - Oral session

View
Integrated Physiology/Obesity

New Insights from the Restoring Insulin Secretion (RISE) Study—Differences between Adults and Youth with Prediabetes and Type 2 Diabetes

Sharon Edelstein, ScM; Thomas A. Buchanan, MD; Kristina Utzschneider, MD; Kristen J. Nadeau, MD, MS

Expert commentary by Dana M. Dabelea, MD, PhD

ADA 2020 - Oral session

View
Integrated Physiology/Obesity

Glycaemia, Beta-Cell Function, and Incretin Hormones Post-OGTT One Year after Gastric Bypass and Sleeve Gastrectomy in Patients with Morbid Obesity and Type 2 Diabetes: An RCT (Oseberg Study)

Farhat Fatima, MD

Expert Commentary by Prof. Tatjana Milenkovic, MD

ADA 2020 - Oral session

View
Therapeutics/New Technology

Differences in Time-in-Range, Glycemic Variability, and the Glucose Management Indicator in Pregnant Women with Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes

Sarit Polsky, MD

Expert commentary by Denice Feig, MD, MSc, FRCPC

ADA 2020 - Oral session

View